Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide: III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia

Fazzi, Rita; Galimberti, Sara; Pacini, Simone; Testi, Rossana; Azzarà, Antonio; Orciuolo, Enrico; Trombi, Luisa; Metelli, Maria Rita; Petrini, Mario

doi:10.1016/j.leukres.2004.01.019

« Previous Next »Leukemia Research
Volume 28, Issue 10 , Pages 1097-1105, October 2004

Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide:

III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia

Rita Fazzi
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
Sara Galimberti
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
Simone Pacini
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
Rossana Testi
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
Antonio Azzarà
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
Enrico Orciuolo
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
Luisa Trombi
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
Maria Rita Metelli
- Department of Experimental Pathology, Medical Biotechnologies, Infectious Diseases and Epidemiology, University of Pisa, Pisa, Italy
Mario Petrini
- Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
- Corresponding author. Tel.: +39-050-992815; fax: +39-050-830162.

Received 1 September 2003; accepted 2 January 2004.

Abstract

The increase of megakaryocytes and platelets that characterizes essential thrombocythemia (ET) appears to be secondary to a deregulation of megakaryocytopoiesis. The carboxy-terminal fragment of osteogenic growth peptide (OGP10–14) promotes bone formation and hemopoiesis, while it inhibits megakaryocytopoiesis. In this paper we show that treatment with synthetic OGP10–14 (sOGP10–14) induces a significant reduction of mid and large colony-forming unit-megakaryocytes (CFU-Mk) in ET patients as well as in controls, and is associated with a significant inhibition of thrombopoietin (TPO)-primed MO-7e megakaryoblastic cells proliferation. These actions appear to be related to sOGP10–14 modulation of TGF-β₁ synthesis and/or secretion, although a direct effect on TGF-β receptor expression cannot be excluded.

Keywords: OGP10–14, Megakaryocytopoiesis, Essential thrombocythemia, TGF-β₁, CFU-Mk